secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2026-02-06T23:59:59+00:00
Accession:  0001493152-26-005554
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics appoints Gregg C. E. Johnson as independent director
-----------------------------------------------------------------------

- Gregg C. E. Johnson appointed independent director effective Feb 4, 2026; will serve on Compensation Committee.
- Annual cash fee of $48,000 plus $5,000 per committee membership; eligible for stock options under 2024 Equity Incentive Plan.
- Johnson previously served as Secretary (2016-2020) and director (2016-2018) of Vivos; has law degree and experience in emerging companies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226005554/0001493152-26-005554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226005554/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-005554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer